Psilocybin is closer to becoming an FDA-approved medical treatment than any classic psychedelic in history and it's still, as of this writing, a Schedule I controlled substance outside a small number of specific state programs and clinical trials. Both facts are true simultaneously, and understanding the actual landscape matters, particularly given how much promotional content blurs the line between "promising research" and "currently accessible treatment."
The most advanced program is COMPASS Pathways' COMP360, a synthetic psilocybin formulation being studied for treatment-resistant depression. It has achieved two consecutive positive Phase 3 trials COMP005 in mid-2025 and COMP006 in early 2026 both meeting primary endpoints with strong statistical significance, and positive longer-term durability data followed in mid-2026. The company's regulatory submission is underway, with a potential FDA approval decision projected for late 2026 or early 2027, and a possible U.S. launch in the first half of 2027 if approved. This would make it the first classic psychedelic ever approved by the FDA.
A second program, from the Usona Institute, is following a similar path and has also received an FDA priority review voucher, placing it near the front of the regulatory queue.
Despite this research momentum, psilocybin remains a Schedule I controlled substance federally meaning possession and use outside authorized research or a specific licensed state program remains illegal under federal law. An executive order signed in April 2026 directed federal agencies to prioritize and accelerate review of psychedelic therapies with breakthrough designation and opened a pathway for parallel rescheduling review but this changes process and priority, not psilocybin's legal status itself. Any eventual rescheduling would likely apply specifically to an approved formulation like COMP360, not to psilocybin as a substance generally.
| Pathway | Current Status |
|---|
| Oregon | Licensed, supervised psilocybin service centers operating since 2023; not covered by insurance |
| Colorado | Regulated healing center program, with dozens of licensed centers operating as of 2026 |
| Connecticut | State pilot program expanded in June 2026 to adults 18+ meeting clinical eligibility criteria, operated within FDA-approved research at a state medical school |
| Clinical trials nationwide | Legal access under FDA-supervised research protocols, available even in states where psilocybin is otherwise prohibited |
Notably, none of these state-level pathways are covered by insurance, since they exist outside FDA approval cost is currently an out-of-pocket consideration regardless of which legal pathway someone accesses.
Regulatory and medical sources are consistent and direct on this point: COMP360 and similar formulations are not yet approved, and seeking psilocybin therapy through unregulated retreat programs, informal facilitators, or online sources carries real legal risk and real health risk including the absence of the medical screening, controlled setting, and trained clinical supervision that the actual research protocols are built around specifically to manage risk. "Promising research" is not the same as "safe to access anywhere."
- If you have treatment-resistant depression, discuss current FDA-approved options including esketamine (Spravato) with a psychiatrist while psilocybin's approval process continues, rather than waiting on an uncertain timeline.
- If considering a legal state-level program (Oregon or Colorado specifically), confirm the facility is properly licensed under that state's specific regulatory framework, and understand it will not be covered by insurance.
- Clinical trials remain a legal access pathway in some cases ClinicalTrials.gov can help identify currently enrolling studies, and COMPASS Pathways and Usona Institute both post updates on active trial sites.
- Be skeptical of any provider or program that downplays psilocybin's current Schedule I status or overstates how close approval actually is.
Frequently asked questions
Not federally it remains a Schedule I controlled substance as of 2026, except within specific licensed state programs (currently Oregon, Colorado, and a Connecticut pilot program) or FDA-supervised clinical trials.
COMPASS Pathways' COMP360 is furthest along, with a potential approval decision projected for late 2026 or early 2027 based on current regulatory submission timelines though approval is not guaranteed and timelines can shift.
Not currently, including in state-legal programs like Oregon and Colorado, since these exist outside FDA approval. Insurance coverage would require a separate approval decision from FDA, followed by decisions from CMS and individual insurers.
Yes this is a legal access pathway even in states where psilocybin is otherwise prohibited, provided it's through a properly registered FDA-supervised trial. ClinicalTrials.gov is a reliable way to check current enrollment.
This carries real legal and health risk. Regulated programs and clinical trials include medical screening and trained supervision specifically designed to manage risk protections that aren't guaranteed in unregulated settings.
No it directs federal agencies to prioritize and accelerate review of psychedelic therapies and opens a pathway for parallel rescheduling review, but psilocybin remains Schedule I federally as of this writing, and any rescheduling would likely apply to a specific approved formulation, not the substance broadly.
This article was reviewed by the RehabsNearMe Editorial Team for accuracy, clarity, and relevance. Information may be sourced from publicly available treatment resources, government agencies, and healthcare references where applicable.
Last reviewed: August 2026
Related articles
Resources
